Table 3.

Etiology, treatment, and outcome of adult-onset hypophosphatemic osteomalacia

	Etiology	Onset to diagnosis (mo)	ADV dose (mg/d)	ADV duration (yr)	Medication change	Time to symptom improvement (mo)	Time to normalization of phosphate (mo)
1	Tumor-induced osteomalacia	25	N/A	N/A	N/A	7 d	2 d
2	ADV-induced nephropathy	25	10	6	Keep ADV	3	Never
3	ADV-induced nephropathy	24	10	11	Change to ETV	0.5	3.5
4	ADV-induced nephropathy	6	10	10	Discontinuation of ADV	3	3
5	ADV-induced nephropathy	9	Unknown	11	Change to ETV	2	8
6	Light-chain nephropathy due to multiple myeloma	14	N/A	N/A	N/A	1	Never
7	ADV-induced nephropathy	27	10	4	Change to ETV	2	9
8	ADV-induced nephropathy	61	10	7	Change to TAF	1	1

N/A: Not applicable; ADV: Adefovir; ETV: Entecavir; TAF: Tenofovir alafenamide fumarate.